Human Metapneumovirus and Human Parainfluenza Infection

Infectious Diseases
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
2100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Moderna
ModernaCAMBRIDGE, MA
2 programs
2
mRNA-1653Phase 1RNA Therapeutic1 trial
mRNA-1653Phase 1RNA Therapeutic1 trial
Active Trials
NCT04144348Completed51Est. Dec 2022
NCT03392389Completed124Est. Jul 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ModernamRNA-1653
ModernamRNA-1653

Clinical Trials (2)

Total enrollment: 175 patients across 2 trials

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

Start: Nov 2019Est. completion: Dec 202251 patients
Phase 1Completed

Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

Start: Dec 2017Est. completion: Jul 2019124 patients
Phase 1Completed

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space